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ABSTRACT 
Th e co-administration of several drugs in multidrug ther-
apy may alter the binding of each drug to human serum albu-
min (HSA) and, thus, their pharmacology eﬀ ect. Th erefore, in 
this study, the interaction mechanism between HSA and two 
ﬂ uoroquinolones (FQs), sparﬂ oxacin (SPF) and levoﬂ oxacin 
(LVF), was investigated using ﬂ uorescence and absorption 
methods in the absence and presence of the competing drug- 
tigecycline (TGC). Th e the UV-Vis and ﬂ uorescence spectros-
copy results showed that the ﬂ uorescence quenching of HSA 
was a result of the formation of the HSA-SPF and HSA-LVF 
complexes. Th e ﬂ uorescence quenching of HSA-TGC revealed 
that tigecycline can regulate the binding sites, binding mode 
and binding aﬃ  nity of ﬂ uoroquinolones. Th e binding con-
stants (KA) and binding sites (n) of the interaction systems 
were calculated. Th e results conﬁ rmed that the KA values of 
the HSA-FQ system decreased in the presence of TGC, indi-
cating that TGC can aﬀ ect the binding ability of FQ for HSA. 
Th is interaction may increase the free plasma concentration of 
unbound FQ and enhance their pharmacology eﬀ ect.
Keywords: Fluorescence, Human serum albumin, Fluo-
roquinolones, Tigecycline.
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SAŽETAK 
Istovremena primena nekoliko lekova, u multilek tera-
piji, može izmeniti njihovo vezivanje za humani serumski 
albumin (HSA) i njihov farmakološki efekat. Zbog toga, u 
ovom radu je proučavan mehanizam interakcije između 
HSA i dva ﬂ uorohinolona (FQs): sparﬂ oksacina (SPF) i le-
voﬂ oksacina (LVF) ﬂ uorescentnim i apsorpcionim metoda-
ma u odsustvu i prisustvu konkurentskog leka - tigeciklina 
(TGC). Rezultati UV-Vis i ﬂ uorescentne spektroskopije su 
pokazali da je gašenje ﬂ uorescencije u HSA rezultat formira-
nja HSA-SPF i HSA-LVF kompleksa. Gašenje ﬂ uoroscencije 
u HSA-TGC je pokazalo da tigeciklin može regulisati mesta 
vezivanja, način vezivanja i aﬁ nitet vezivanja ﬂ uorohinolo-
na. Konstante vezivanja (KA) i broj vezujićih mesta (n) za 
interakcije u sistemu su izračunate. Rezultati su potvrdili da 
su vrednosti KA u HSA-FQ sistemu, smanjene u prisustvu 
TGC, a to ukazuje da TGC može da utiče na sposobnost 
vezivanja FQ za HSA. Ova interakcija može povećati slo-
bodanu koncentraciju u plazmi nevezanog FQ i poboljšati 
njegov farmakološki efekat.
Keywords: Fluorescencija, Humani serumski albumin, 
Fluorohinoloni, Tigeciklin.
INTRODUCTION
Human serum albumin (HSA) presents the most abun-
dant serum protein in human plasma. HSA plays an impor-
tant role in controlling distribution, excretion, therapeutic 
efficacy and drug toxicity in the human body (1-3). HSA 
possesses several low- and high-affinity ligand binding sites 
that have been identified as site I and site II. Each domain 
can be subdivided into subdomains A and B and is respon-
sible for the binding of most drugs with the HSA (4, 5).
Whenever co-administration of several drugs is need-
ed, their competition for the same binding site or confor-
mational changes in protein may occur. This leads to the 
increased or decreased concentration of the free drug frac-
tion, which results in an enhanced or reduced therapeutic 
efficacy of the drug. Fluoroquinolones (FQs) belong to a 
group of antibacterial agents. Their mechanism of action 
consists of inhibiting different kinds of enzymes, such as 
homologous type 2, topoisomerase, DNA gyrase and DNA 
topoisomerase 4, which play a crucial role in chromosome 
function and replication (6). Fluoroquinolones have a wide 
range of use. Their application has been reported in an em-
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pirical treatment of a variety of infections, especially in the 
genitourinary, gastrointestinal and respiratory tracts. Tige-
cycline possesses a similar mechanism of action to tetra-
cyclines and acts by binding to the bacterial 30S ribosomal 
subunit and inhibiting protein synthesis (7, 8). Tigecycline 
has been approved for treating complicated intra-abdom-
inal infections as well as skin and skin structure infections 
(9). The chemical structures of the investigated drugs are 
shown in Fig. 1.  
Spectral methods can reveal the binding of drugs with 
albumin at low concentrations. The fluorescence quench-
ing technique is often used to monitor molecular interac-
tions because of its high sensitivity, reproducibility and 
relatively easy use (10, 11). In the present study, the inter-
actions of sparfloxacin and levofloxacin with HSA and the 
effect of tigecycline on these interactions by UV-Vis and 
fluorescence spectroscopy were investigated. Additionally, 
the binding of TGC to HSA was determined in our previ-
ously published research (12). 
MATERIAL AND METHODS
Chemical and reagents.
Human serum albumin (HSA, lyophilized powder, free 
fatty acid ≤0.007%, purity ≥96%, catalogue No. A1887), 
sparfloxacin (SPF, purity ≥98%, catalogue No. 56968), levo-
floxacin (LVF, purity ≥98%, catalogue No. 28266) and tige-
cycline (TGC, tigecycline hydrate, purity ≥98%, catalogue 
No. PZ0021) were purchased from the Sigma-Aldrich 
Chemical Company (St. Louis, MO, USA). The stock so-
lutions of HSA (20 μmol/L), SPF (0.11 mmol/L), LVF (0.1 
mmol/L) and TGC (85.38 μmol/L) were prepared fresh in 
phosphate buffer (pH 7.4; 0.1 mol/L) containing 0.15 mol/L 
NaCl, that which was selected to keep the pH value and 
maintain the ionic strength of the solution. All the above 
solutions were kept in the dark at 0-4°C in a refrigerator. 
The sample masses were accurately weighed on a micro-
balance (Sartorius, ME215S) with a resolution of 0.1 mg. 
pH measurements were performed with a Beckman F-72 
pH meter. All reagents were of analytical reagent grade and 
used without further purification. Newly double-distilled 
water was used throughout the experiment.
UV-Vis and fluorescence spectroscopy.
The absorption spectra were recorded on a double 
beam Lambda 25 UV/Vis Spectrophotometer (Perki-
nElmer, USA) equipped with 1.0 cm quartz cells. Fluores-
cence spectra were recorded using a RF-1501 PC spectro-
fluorometer (Shimadzu, Japan) equipped with a 150 W 
Xenon lamp source, a 1.0-cm path-length quartz cell and 
a thermostatic cuvette holder. The excitation and emission 
bandwidths were both 10 nm.
In each combination, the quenching of HSA fluores-
cence by fluoroquinolone (FQ) was studied in the absence 
and presence of the competing drug, tigecycline (TGC). 
In the first set of experiments, the binding of each drug 
to HSA was studied under the same experimental condi-
tions. The concentration of HSA was fixed at 2.0 μmol/L, 
and those of SPF and LVF were varied. In the second set of 
experiments, the binding of FQ to HSA was determined 
simultaneously with TGC. The concentrations of HSA and 
Fig. 1. Chemical structures of sparﬂ oxacin (A), levoﬂ oxacin (B) and tigecycline (C).
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TGC were fixed at 2.0 μmol/L, and the concentrations of 
SPF and LVF were varied. The same sets of samples were 
used to obtain the UV-Vis spectra. All measurements were 
performed at a temperature of 298 K.
RESULTS 
Fluorescence studies.
The intrinsic fluorescence of HSA when it is excited at 
295 nm is due primarily to the presence of the two tryp-
tophan residues: Trp-134 and Trp-212. Trp-212 is located 
within a hydrophobic binding pocket in the IIA sub-domain 
of the protein, and Trp-134 is located on the surface of the 
albumin molecule and is more exposed to the environment 
(13). Although the tyrosine residue can also contribute to 
fluorescence, it presents a very weak emission (14). An im-
portant characteristic of the intrinsic fluorescence of HSA 
is that it is very sensitive to its microenvironment; it would 
be quenched if there is even a small change in the local 
surroundings of HSA, such as the biomolecular binding, 
protein conformation and denaturation (15). All fluores-
cence emission spectra were recorded from 300 to 450 nm, 
with excitation at 295 nm. It was necessary to distinguish 
between the static fluorescence quenching mode (resulting 
from the formation of a ground state complex between the 
fluorophore and the quencher) and the dynamic quench-
ing mode (resulting from a collision between the fluoro-
phore and the quencher). To confirm the quenching mech-
anism, the fluorescence data were analyzed at 298 K using 
the well-known Stern–Volmer Eq. (1) (16):
                      (1)
where F and F0 are the fluorescence intensities of the 
protein in the presence and absence of the quencher, re-
spectively. Kq is the quenching rate constant of the biomol-
ecule, [Q] is the quencher concentration, KSV is the Stern−
Volmer constant and τ0 is the lifetime of the fluorophore in 
the absence of the quencher [τ0 is approximately 10−8 s]. If 
the biomolecular quenching constants are larger than the 
limiting diffusion rate constant of the biomolecule [2.0 x 
1010 L M−1 s−1] (17), the quenching is initiated not by the 
dynamic collision, but by the protein complex.
For the static quenching process, when small mole-
cules bind independently to a set of equivalent sites on a 
biomacromolecule, the equilibrium between the free and 
bound molecules could be represented by the well-known 
Eq. (2) (16-18):
                                (2)
where KA is the binding constant or the apparent as-
sociation constant for drug-protein interaction, n is the 
number of binding sites per HSA molecule and [Q] is the 
concentration of quencher.
The quenching of the intrinsic fluorescence of HSA by 
sparfloxacin and levofloxacin was studied. The fluores-
cence spectra of HSA were recorded in the presence of in-
creasing amounts of FQ (Fig. 2 and Fig. 3). 
As shown in Fig. 2 and Fig. 3, the fluorescence intensity 
of HSA decreased regularly with increasing concentrations 
of FQ, but the emission maximum and shape of the peaks 
remained almost unchanged. This indicated that SPF and 
LVF could bind to HSA. Upon drug binding, the fluores-
cence spectra of HSA were accompanied by a shift in emis-
sion wavelength towards a lower wavelength (blueshift) in 
the case of SPF and towards a higher wavelength (redshift) 
in the case of LVF. These results are in accordance with the 
previous study (19). The blue/redshift in the emission wave-
length (λmax) suggests a change in the hydrophobicity of the 
microenvironment of the drug binding region (20, 21).
Fig. 2. Th e ﬂ uorescence quenching spectra of HSA by SPF (T = 298 K, pH = 7.4). [HSA] = 2.0 μmol/L; 
[SPF] (a-k): (0, 1.1, 1.65, 2.2, 2.75, 3.3, 4.4, 5.5, 6.6, 8.8, 11.0) μmol/L. Th e lower insert shows Stern–Vol-
mer plots of the ﬂ uorescence quenching of HSA by SPF. 
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Fig. 4. Th e ﬂ uorescence quenching spectra of HSA by SPF in the presence of TGC (T = 298 K, pH = 7.4). 
[HSA] = 2.0 μmol/L; [SPF] (a-i): (0, 1.65, 2.75, 3.3, 5.5, 6.6, 8.8, 10.0, 11.0) μmol/L; [TGC] = 2.0 μmol/L. 
Th e lower insert shows Stern–Volmer plots of the ﬂ uorescence quenching of HSA by SPF in the pres-





























λ = 350 nm
Fig. 3. Th e ﬂ uorescence quenching spectra of HSA by LVF (T = 298 K, pH = 7.4). [HSA] = 2.0 μmol/L; 
[LVF] (a-i): (0, 1.16, 2.34, 3.52, 4.68, 5.86, 7.03, 8.2, 9.38) μmol/L. Th e under insert is Stern–Volmer 





























λ = 350 nm
Fig. 5. Th e ﬂ uorescence quenching spectra of HSA by LVF in the presence of TGC (T = 298 K, pH = 
7.4). [HSA] = 2.0 μmol/L; [LVF] (a-i): (0, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 5.0) μmol/L; [TGC] = 2.0 μmol/L. 
Th e under insert is Stern–Volmer plots of the ﬂ uorescence quenching of HSA by LVF in the presence 
of ﬁ xed TGC concentration.
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Drug–drug interactions at the protein-binding level 
can be useful for therapeutic purposes because an altera-
tion in protein binding may change the volume of dis-
tribution, clearance, and elimination of a drug and may 
modulate its therapeutic effect (22, 23). The binding af-
finity of FQs for HSA in the presence of TGC and the 
competitive binding mechanism were investigated. The 
fluorescence spectra of the HSA-TGC complex were re-
corded in the presence of an increasing amount of FQs 
(Fig. 4 and Fig. 5). Increasing the concentration of FQs 
led to an increased quenching fluorescence signal of the 
HSA-TGC complex (Fig. 4 and Fig. 5), suggesting that 
FQs interact with the HSA-TGC complex. Therefore, 
sparfloxacin and levofloxacin can displace TGC from its 
binding site, which means that TGC and these drugs may 
share some common binding sites in HSA. 
UV-Vis absorption studies.
UV-Vis absorption measurement is a very simple 
method and can be used to explore the structural chang-
es and determine complex formations (15, 24). HSA has 
a weak absorption peak at approximately 280 nm be-
cause of cumulative absorption of three aromatic amino 
acid residues (Trp, Tyr and Phe). The absorbance peak 
around 280 nm is raised, which is mainly caused by the 
π–π* transition of aromatic amino acid residues in HSA 
(25, 26). In the present study, the changes in the UV-Vis 
absorption spectra of the HSA-LVF system (Fig. 6) and 
HSA-SPF (Fig. 7) were measured under the simulated 
physiological conditions. Additionally, the UV-Vis ab-
sorption spectra of the HSA-SPF and HSA-LVF system 
were measured in the presence of the fixed TGC con-
centration (Fig. 8 and Fig. 9). 
Fig. 6. Absorption spectra of HSA in the presence of various LVF concentrations (T = 298 K, pH = 7.4). 




























λ = 280 nm
Fig. 7. Absorption spectra of HSA in the presence of various SPF concentrations (T = 298 K, pH = 
7.4). [HSA] = 2.0 μmol/L; [SPF] (a-k): (0, 1.10, 1.65, 2.2, 2.75, 3.3, 4.4, 5.5, 6.6, 8.8, 11.0) μmol/L. x 




























λ = 280 nm
Fig. 9. Absorption spectra of HSA in the presence of various SPF and ﬁ xed TGC concentration (T 
= 298 K, pH = 7.4). [HSA] = 2.0 μmol/L; [SPF] (a-k): (0, 1.1, 1.65, 2.2, 2.75, 3.3, 4.4, 5.5, 6.6, 8.8, 11.0) 
μmol/L; [TGC] = 2.0 μmol/L. x represents 2.0 μmol/L SPF only.  
Fig. 8. Absorption spectra of HSA in the presence of various LVF concentrations and a ﬁ xed TGC con-
centration (T = 298 K, pH = 7.4). [HSA] = 2.0 μmol/L; [LVF] (a-i): (0, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 5.0) 
μmol/L; [TGC] = 2.0 μmol/L. x represents 2.0 μmol/L LVF only. 
DISCUSSION
Fluorescence and absorption spectra.
The fluorescence intensity of HSA and HSA-TGC de-
creased regularly with increasing FQ concentrations (Figs. 
2, 3, 4 and 5). The quenching mechanism was determined to 
investigate whether FQs interact with HSA and HSA-TGC 
to form a complex. To confirm the quenching mechanism, 
the fluorescence quenching data were analyzed according to 
the Stern-Volmer Eq. 1. Eq. 1 was applied to determine KSV 
via the linear regression of a plot of F0/F against [Q]. The KSV 
was then obtained from the slope. The values of KSV and Kq 
were calculated and are given in Table 1. Stern–Volmer plots 
for the fluorescence quenching of HSA and HSA-TGC by 
SPF and LVF are shown in the inserts in Figs. 2 , 3, 4 and 5. 
The Stern–Volmer plots (Figs. 2, 3, 4 and 5) showed a linear 
curve for all of the investigated concentrations, which indi-
cates that quenching type can be static or dynamic quench-
ing because the characteristic Stern–Volmer plots of com-
bined quenching (both static and dynamic) show an upward 








HSA-TGC (12) 4.99 0.996 1.76 0.91 0.991
HSA-SPF 2.35 0.990 10.75 1.13 0.991
HSA-SPF-TGC 3.32 0.987 7.56 1.08 0.990
HSA-LVF 3.31 0.986 9.24 1.09 0.992
HSA-LVF-TGC 5.87 0.995 2.74 0.94 0.995
Table 1. Th e quenching constants (Kq), binding constants (KA) and num-
ber of binding sites (n) of HSA-FQ systems in the absence and presence 
of TGC at 298 K.
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dicating that with the addition of FQ, the peptide strands 
of the HSA molecules extended farther and the hydro-
phobicity was changed (33). 
Binding parameters.
The quenching mechanism was determined to be static 
quenching; thus, the binding constant (KA) and the num-
ber of binding sites (n) can be calculated according to Eq. 
2. The values of KA and n of all systems were obtained from 
the intercept and slope of the plots of log (F0−F)/F versus 
log [Q] (Figs. 10 and 11).
The values of the binding constant KA and of n are given 
in Table 1. The number of binding sites (n) is approximately 
1, indicating that there is one binding site in HSA for SPF and 
LVF. The binding constants of the HSA-SPF and HSA-LVF 
system that were found in this research are in agreement 
with previous studies (34, 35). The relatively high values of 
the stability constants suggest a strong interaction between 
define the quenching type. Thus, based on previous works 
(28-31), the possible quenching mechanism between HSA 
and fluoroquinolones was suggested to be static quenching 
resulting from the complex formation instead of dynamic 
quenching. As evident from the results (Table 1), the Kq val-
ues (>1012 L/mol∙s) are higher than those of diverse kinds of 
quenchers that are used for biopolymer fluorescence (2.0 × 
1010 L/mol∙s). These results indicate that the quenching was 
initiated not from a dynamic collision, but from the forma-
tion of a complex in all of the tested systems.
The absorption spectra of HSA and HSA-TGC at dif-
ferent concentrations of FQ (Figs. 6, 7, 8 and 9) showed 
that in the visible region, the absorbance values of HSA 
and HSA-TGC increased regularly with an increase in 
the concentration of FQ, suggesting that a complex was 
formed between FQs and HSA and between FQs and 
HSA-TGC (32). The absorption peaks of these solutions 
showed moderate shifts towards a longer wavelength, in-
Fig. 10. Plots of log (F0−F)/F versus log [Q] of HSA-SPF and HSA-SPF-TGC system at 298 K. 
Fig. 11. Plots of log (F0−F)/F versus log [Q] of HSA-LVF and HSA-LVF-TGC system at 298 K. 
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HSA with high affinity. The results confirmed that the bind-
ing constant (KA) values of the HSA-FQ system decreased 
in the presence of TGC, indicating that TGC can affect the 
binding ability of FQ for HSA. This may increase the free 
plasma concentration of unbound FQ and enhance their 
pharmacological and toxicological effects. Studies on the 
interaction between plasma proteins and small molecule-
drugs are thus an interesting field of future research. 
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